EXECUTIVES
Biotechnology movers and shakers on the move. Read new hires, promotions of executives, and more.
Mark Mullikin Appointed Vedanta Biosciences CFO
Mullikin brings 25 years of experience raising and deploying capital for life sciences companies and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis.
Dr. Caigan Du to Serve on Creative Medical Technology Scientific Advisory Board
Dr. Caigan Du is Associate Professor at the University of British Columbia. He is a top researcher in the area of molecular and immunological understanding of kidney failure and transplant rejection.
Robert Glassman MD Appointed to Jubilant Therapeutics Board of Directors
Dr. Glassman will serve as an independent, non-executive director, effective February 1, 2021.
Indapta Therapeutics Announces New Appointments
Indapta Therapeutics notes Lori Kunkel, M.D., was appointed Senior Clinical Advisor, Robert Sikorski, M.D., Ph.D., as its Founding Chief Medical Officer, and Jim Weiss as a member of its Board of Directors.
STERIS Announces Leadership Succession Plan
Walt Rosebrough, President, and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS’s leadership and Board for the next two years.
Kymera Therapeutics Strengthens Leadership
Ashwin Gollerkeri, MD, appointed as Senior Vice President, Head of Development, and Kevin Dushney, as Vice President, Information Technology, as well as the promotion of Karen Martin, JD, Ph.D. to Vice President, Head of Legal.